Soft Tissue Sarcoma Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Targeted Therapy, Chemotherapy, Anti-angiogenesis drugs, Radiation Therapy, Internal Radiation Therapy, External Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Long-Term Care Centres) and Region

Soft Tissue Sarcoma Treatment Market size was valued at US$ 3,595.4 million in 2023 and is poised to grow at a CAGR of 7.3% from 2024 to 2030. Soft tissue sarcoma is a rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, deep skin tissues, etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develops from fat cells, and leiomyosarcomas, which arises from smooth muscle tissue.

The soft tissue sarcoma can be treated by combined chemotherapy, radiotherapy, and surgery to remove the tumor. If the surgical procedure is not required, chemotherapy alone can be used. The soft tissue sarcoma treatment market is in the growing stage as very few products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities.

For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all ifosfamide development expenses. GSK's Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as a first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Key Developments

• In Sept 2024: Clinical-stage biopharmaceutical company, Actuate Therapeutics, Inc, focused on developing therapies that target high-impact, difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta, or GSK-3β, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to elraglusib, a novel, first-in-class GSK-3β inhibitor in the treatment of soft tissue sarcoma.              
• In Aug 2024: Adaptimmune Therapeutics plc is a company that is focused on changing the treatment paradigm of solid tumour cancers by exploiting the body's natural defence system. The company announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. TECELRA is the first engineered cell therapy for any solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most often strikes young adults.